These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
284 related articles for article (PubMed ID: 29254858)
1. Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial. Shepstone L; Lenaghan E; Cooper C; Clarke S; Fong-Soe-Khioe R; Fordham R; Gittoes N; Harvey I; Harvey N; Heawood A; Holland R; Howe A; Kanis J; Marshall T; O'Neill T; Peters T; Redmond N; Torgerson D; Turner D; McCloskey E; Lancet; 2018 Feb; 391(10122):741-747. PubMed ID: 29254858 [TBL] [Abstract][Full Text] [Related]
2. Management of Patients With High Baseline Hip Fracture Risk by FRAX Reduces Hip Fractures-A Post Hoc Analysis of the SCOOP Study. McCloskey E; Johansson H; Harvey NC; Shepstone L; Lenaghan E; Fordham R; Harvey I; Howe A; Cooper C; Clarke S; Gittoes N; Heawood A; Holland R; Marshall T; O'Neill TW; Peters TJ; Redmond N; Torgerson D; Kanis JA; J Bone Miner Res; 2018 Jun; 33(6):1020-1026. PubMed ID: 29480960 [TBL] [Abstract][Full Text] [Related]
3. Long-term cost-effectiveness of screening for fracture risk in a UK primary care setting: the SCOOP study. Söreskog E; Borgström F; Shepstone L; Clarke S; Cooper C; Harvey I; Harvey NC; Howe A; Johansson H; Marshall T; O'Neill TW; Peters TJ; Redmond NM; Turner D; Holland R; McCloskey E; Kanis JA; Osteoporos Int; 2020 Aug; 31(8):1499-1506. PubMed ID: 32239237 [TBL] [Abstract][Full Text] [Related]
4. Screening for high hip fracture risk does not impact on falls risk: a post hoc analysis from the SCOOP study. Condurache CI; Chiu S; Chotiyarnwong P; Johansson H; Shepstone L; Lenaghan E; Cooper C; Clarke S; Khioe RFS; Fordham R; Gittoes N; Harvey I; Harvey NC; Heawood A; Holland R; Howe A; Kanis JA; Marshall T; O'Neill TW; Peters TJ; Redmond NM; Torgerson D; Turner D; McCloskey E; Osteoporos Int; 2020 Mar; 31(3):457-464. PubMed ID: 31960099 [TBL] [Abstract][Full Text] [Related]
5. Fracture prevention by screening for high fracture risk: a systematic review and meta-analysis. Merlijn T; Swart KMA; van der Horst HE; Netelenbos JC; Elders PJM Osteoporos Int; 2020 Feb; 31(2):251-257. PubMed ID: 31838551 [TBL] [Abstract][Full Text] [Related]
6. The Effect of a Screening and Treatment Program for the Prevention of Fractures in Older Women: A Randomized Pragmatic Trial. Merlijn T; Swart KM; van Schoor NM; Heymans MW; van der Zwaard BC; van der Heijden AA; Rutters F; Lips P; van der Horst HE; Niemeijer C; Netelenbos JC; Elders PJ J Bone Miner Res; 2019 Nov; 34(11):1993-2000. PubMed ID: 31220365 [TBL] [Abstract][Full Text] [Related]
7. A pragmatic randomised controlled trial of the effectiveness and cost-effectiveness of screening older women for the prevention of fractures: rationale, design and methods for the SCOOP study. Shepstone L; Fordham R; Lenaghan E; Harvey I; Cooper C; Gittoes N; Heawood A; Peters T; O'Neill T; Torgerson D; Holland R; Howe A; Marshall T; Kanis J; McCloskey E Osteoporos Int; 2012 Oct; 23(10):2507-15. PubMed ID: 22314936 [TBL] [Abstract][Full Text] [Related]
9. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study. McClung MR; O'Donoghue ML; Papapoulos SE; Bone H; Langdahl B; Saag KG; Reid IR; Kiel DP; Cavallari I; Bonaca MP; Wiviott SD; de Villiers T; Ling X; Lippuner K; Nakamura T; Reginster JY; Rodriguez-Portales JA; Roux C; Zanchetta J; Zerbini CAF; Park JG; Im K; Cange A; Grip LT; Heyden N; DaSilva C; Cohn D; Massaad R; Scott BB; Verbruggen N; Gurner D; Miller DL; Blair ML; Polis AB; Stoch SA; Santora A; Lombardi A; Leung AT; Kaufman KD; Sabatine MS; Lancet Diabetes Endocrinol; 2019 Dec; 7(12):899-911. PubMed ID: 31676222 [TBL] [Abstract][Full Text] [Related]
10. Can frailty in conjunction with FRAX identify additional women at risk of fracture - a longitudinal cohort study of community dwelling older women. Bartosch P; Malmgren L BMC Geriatr; 2022 Dec; 22(1):951. PubMed ID: 36494774 [TBL] [Abstract][Full Text] [Related]
11. The Cost-Effectiveness of Screening in the Community to Reduce Osteoporotic Fractures in Older Women in the UK: Economic Evaluation of the SCOOP Study. Turner DA; Khioe RFS; Shepstone L; Lenaghan E; Cooper C; Gittoes N; Harvey NC; Holland R; Howe A; McCloskey E; O'Neill TW; Torgerson D; Fordham R; J Bone Miner Res; 2018 May; 33(5):845-851. PubMed ID: 29470854 [TBL] [Abstract][Full Text] [Related]
12. Effectiveness of a two-step population-based osteoporosis screening program using FRAX: the randomized Risk-stratified Osteoporosis Strategy Evaluation (ROSE) study. Rubin KH; Rothmann MJ; Holmberg T; Høiberg M; Möller S; Barkmann R; Glüer CC; Hermann AP; Bech M; Gram J; Brixen K Osteoporos Int; 2018 Mar; 29(3):567-578. PubMed ID: 29218381 [TBL] [Abstract][Full Text] [Related]
13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of osteoporosis screening strategies for hip fracture prevention in older Chinese people: a decision tree modeling study in the Mr. OS and Ms. OS cohort in Hong Kong. Su Y; Lai FTT; Yip BHK; Leung JCS; Kwok TCY Osteoporos Int; 2018 Aug; 29(8):1793-1805. PubMed ID: 29774400 [TBL] [Abstract][Full Text] [Related]
15. The Added Value of SARC-F to Prescreening Using FRAX for Hip Fracture Prevention in Older Community Adults. Su Y; Woo JW; Kwok TCY J Am Med Dir Assoc; 2019 Jan; 20(1):83-89. PubMed ID: 30314676 [TBL] [Abstract][Full Text] [Related]
16. Anti-osteoporosis drug prescribing after hip fracture in the UK: 2000-2010. Klop C; Gibson-Smith D; Elders PJ; Welsing PM; Leufkens HG; Harvey NC; Bijlsma JW; van Staa TP; de Vries F Osteoporos Int; 2015 Jul; 26(7):1919-28. PubMed ID: 25963232 [TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness of the Screening for the Primary Prevention of Fragility Hip Fracture in Spain Using FRAX Martin-Sanchez M; Comas M; Posso M; Louro J; Domingo L; Tebé C; Castells X; Espallargues M Calcif Tissue Int; 2019 Sep; 105(3):263-270. PubMed ID: 31172231 [TBL] [Abstract][Full Text] [Related]
18. Association of Mental Disorders and Related Medication Use With Risk for Major Osteoporotic Fractures. Bolton JM; Morin SN; Majumdar SR; Sareen J; Lix LM; Johansson H; Odén A; McCloskey EV; Kanis JA; Leslie WD JAMA Psychiatry; 2017 Jun; 74(6):641-648. PubMed ID: 28423154 [TBL] [Abstract][Full Text] [Related]
19. Predicting the 10-year risk of hip and major osteoporotic fracture in rheumatoid arthritis and in the general population: an independent validation and update of UK FRAX without bone mineral density. Klop C; de Vries F; Bijlsma JW; Leufkens HG; Welsing PM Ann Rheum Dis; 2016 Dec; 75(12):2095-2100. PubMed ID: 26984006 [TBL] [Abstract][Full Text] [Related]
20. Association between post-stroke disability and 5-year hip-fracture risk: The Women's Health Initiative. Northuis CA; Crandall CJ; Margolis KL; Diem SJ; Ensrud KE; Lakshminarayan K J Stroke Cerebrovasc Dis; 2020 Aug; 29(8):104976. PubMed ID: 32689623 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]